You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
UV emitting nanoparticles as novel radiation sensitizers targeting hypoxic cells
SBC: RADIATION MONITORING DEVICES, INC. Topic: 102Project Summary Abstract Radiation therapy is one of the primary therapeutic techniques for treating cancer Nearly two thirds of all cancer patients will receive radiation therapy during their illness with an average of radiation treatment episodes Although largely effective radiation therapy like other forms of cancer treatment has difficulty killing hypoxic regions within solid tumors ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Protein ProFiler Microfluidic Electrophoresis System for Proteomics
SBC: INNOVAREGI LLC Topic: 400AbstractThe current estimate of the number of human genes is aboutin contrast to the number of presumed proteinswhich likely exceeds one millionThis increased complexity is the result of post transcriptional and post translational modificationsPTMsoccurring at multiple sites and in a quantitative variable mannerThe overwhelming result is a combinatorially expanding complexity of proteoforms that i ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Amelioration of opioid withdrawal-induced anxiety and craving with heterodyned whole body vibration
SBC: PHOTOPHARMICS, INC. Topic: NIDAPROJECT SUMMARY Opioid use disorder (OUD) is a rising problem in the United States and around the world, with pain and stress being major factors for initial drug seeking and relapse. The mesolimbic dopamine (DA) system originating in the midbrain ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) in the striatum is an important nexus for the rewarding properties of opioids ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
MDCT Quantification of hepatic tumor viability for assessment of cancer therapy
SBC: IQ MEDICAL IMAGING LLC Topic: NCIDESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy (more than 80%) and the third most common cause of death from cancer worldwide. Contrast-enhanced multi-phase multi-detector CT (MDCT) is a routine imaging modality for patients diagnosed with hepatic malignancy. The change of tumor size measured on single-phase (mostly portal-venous p ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses
SBC: IQ MEDICAL IMAGING LLC Topic: 102DESCRIPTION provided by applicant The neurofibromatoses NFs including NF NF and schwannomatosis are a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtually of patients to develop multiple nerve sheath tumors The determination of tumor burden on magnetic resonance imaging MRI images is crucial for the management of NF patients which is ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
MDCT Quantification of hepatic tumor viability for assessment of cancer therapy
SBC: IQ MEDICAL IMAGING LLC Topic: 102Project SummaryAbstract Tumor imaging quantification is critical for diagnosisstagingand treatment evaluationand multi detector CTMDCTis the clinical imaging modality commonly used for patients diagnosed with hepatic malignancy because of its relatively low cost and wide availabilityConventional tumor quantification using either linear or volumetric measurement has demonstrated significant limitat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses
SBC: IQ MEDICAL IMAGING LLC Topic: 102Project SummaryAbstract The neurofibromatosesNFsincluding NFNFand schwannomatosisare a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtuallyof patients to develop multiple nerve sheath tumorsThe determination of tumor burden on magnetic resonance imagingMRIis indispensable for the longitudinal management of NF patientswhich includes life long follow up f ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissues
SBC: FORCYTE BIOTECHNOLOGIES, INC. Topic: NIGMSProject Summary Heart disease remains the leading cause of mortality in the world and, drug-induced cardiotoxicity is a major cause of drug failure and withdrawal from the clinic or the market, contributing to the poor overall success rate of drug development programs. In vitro models of cardiac contractility have the potential to generate predictive data earlier in the pipeline to reduce later-st ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Eliminating the human factor from stereotaxic surgeries
SBC: POPNEURON LLC Topic: 104Project Summary: The main goal of this research project is to develop a new line of new stereotaxic devices for small animal research that outperforms existing devices in terms of accuracy, reproducibility, and ease of use. Advancing a tool such as an electrode, injection pipette or optical fiber through a small hole in the cranium, sometimes over long distances, and placing it precisely in a part ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Modernize animal pharming with emerging gene targeting technologies
SBC: APPLIED STEMCELL, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Animal pharming is the process of using transgenic animals to produce human drugs, mostly in the mammary glands of female animals. The US Food and Drug Administration (FDA) issued its first approval for ATryn, the recombinant human antithrombin III, produced in the milk of transgenic goats in 2009. Prior to FDA approval, this drug gained the approval by the Eu ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health